Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

Br J Haematol. 2019 Feb;184(3):475-479. doi: 10.1111/bjh.15122. Epub 2018 Feb 7.
No abstract available

Keywords: Fcγ receptors; daratumumab; immunotherapy; multiple myeloma; polymorphisms.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics
  • Multiple Myeloma* / mortality
  • Neoplasm Proteins / genetics*
  • Polymorphism, Genetic
  • Receptors, IgG / genetics*
  • Survival Rate

Substances

  • Antibodies, Monoclonal
  • FCGR2A protein, human
  • FCGR2B protein, human
  • Neoplasm Proteins
  • Receptors, IgG
  • daratumumab